To develop cutting-edge epigenomics and computational technologies

With the development of methods for genome-wide mapping of DNA methylation, histone modifications, chromatin accessibility and conformation, high-throughput sequencing has revolutionised the study and our understanding of epigenetics. In this ISPG, we have been at the forefront of methods development, including techniques for identification of new DNA modifications71,72, and low-cell and single-cell epigenomic methods, such as scBS-seq and scM&T-seq23,24. Integral to our IPSG objectives is the adoption and development of state-of-the-art techniques to enable us to interrogate epigenomic dynamics during the lifecourse – to reveal the epigenomes of rare cells (as in early embryos), to uncover cell-to-cell heterogeneity in epigenetic states during key lineage decision making events, and to measure the extent of heterogeneity as a function of ageing – and to integrate multiple parameters towards modelling epigenetic states and transitions. This objective is very much embedded within overall technology development at BI, and through our Sanger Institute/EBI Single Cell Genomics Centre links. This establishes a collaborative Cambridge environment that is hugely conducive to the development of novel epigenomics and computational methods. In addition, we shall extend interactions with industrial collaborators, such as Cambridge Epigenetix Ltd., in particular for developing targeted sequencing, and to commercialise IP we expect to develop in this area.